{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:08:56Z","timestamp":1790255336631,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA119171"],"award-info":[{"award-number":["R01 CA119171"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA210921"],"award-info":[{"award-number":["R01 CA210921"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung and Blood Institute","doi-asserted-by":"crossref","award":["HHSN268201100046C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C, HHSN271201600004C"],"award-info":[{"award-number":["HHSN268201100046C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C, HHSN271201600004C"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dual-outcome intention-to-treat hazard rate analyses have potential to complement single-outcome analyses for the evaluation of treatments or exposures in relation to multivariate time-to-response outcomes. Here we consider pairs formed from important clinical outcomes to obtain further insight into influences of menopausal hormone therapy on chronic disease. As part of the Women\u2019s Health Initiative, randomized, placebo-controlled hormone therapy trials of conjugated equine estrogens (CEE) among posthysterectomy participants and of these same estrogens plus medroxyprogesterone acetate (MPA) among participants with an intact uterus were carried out at 40 US clinical centers (1993\u20132016). These data provide the context for analyses covering the trial intervention periods and a nearly 20-year (median) cumulative duration of follow-up. The rates of multiple outcome pairs were significantly influenced by hormone therapy, especially over cumulative follow-up, providing potential clinical and mechanistic insights. For example, among women randomized to either regimen, hazard ratios for pairs defined by fracture during intervention followed by death from any cause were reduced and hazard ratios for pairs defined by gallbladder disease followed by death were increased, though these findings may primarily reflect single-outcome associations. In comparison, hazard ratios for diabetes followed by death were reduced with CEE but not with CEE + MPA, and those for hypertension followed by death were increased with CEE + MPA but not with CEE.<\/jats:p>","DOI":"10.1093\/aje\/kwaa033","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T11:09:01Z","timestamp":1587035341000},"page":"972-981","source":"Crossref","is-referenced-by-count":16,"title":["Dual-Outcome Intention-to-Treat Analyses in the Women\u2019s Health Initiative Randomized Controlled Hormone Therapy Trials"],"prefix":"10.1093","volume":"189","author":[{"given":"Ross L","family":"Prentice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron K","family":"Aragaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan T","family":"Chlebowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garnet L","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques E","family":"Rossouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Banack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aladdin H","family":"Shadyab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M","family":"Snively","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margery","family":"Gass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn E","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"issue":"6","key":"2020082405571572300_ref1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/gme.0b013e31823a3e5d","article-title":"Evolution of postmenopausal hormone therapy between 2002 and 2009","volume":"19","author":"Ettinger","year":"2012","journal-title":"Menopause"},{"issue":"6","key":"2020082405571572300_ref2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/gme.0b013e31824bb039","article-title":"A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women\u2019s Health Initiative","volume":"19","author":"Steinkellner","year":"2012","journal-title":"Menopause"},{"issue":"6","key":"2020082405571572300_ref3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/GME.0000000000001054","article-title":"Trends in oral and vaginally administered estrogen use among US women 50 years of age and older with commercial health insurance","volume":"25","author":"Weissfeld","year":"2018","journal-title":"Menopause"},{"issue":"6","key":"2020082405571572300_ref4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/GME.0000000000001282","article-title":"Menopausal hormone therapy trends before versus after 2002: impact of the Women\u2019s Health Initiative study results","volume":"26","author":"Crawford","year":"2018","journal-title":"Menopause"},{"issue":"16","key":"2020082405571572300_ref5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast-cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"2020082405571572300_ref6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M13-2348","article-title":"Economic return of the Women\u2019s Health Initiative Estrogen plus Progestin Trial: a modeling study","volume":"160","author":"Roth","year":"2014","journal-title":"Ann Intern Med"},{"issue":"13","key":"2020082405571572300_ref7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"2020082405571572300_ref8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women\u2019s Health Initiative randomized trials","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA"},{"key":"2020082405571572300_ref9","article-title":"Regression models and multivariate life tables","author":"Prentice","journal-title":"J Am Stat Assoc"},{"key":"2020082405571572300_ref10","doi-asserted-by":"crossref","DOI":"10.1201\/9780429162367","volume-title":"The Statistical Analysis of Multivariate Failure Time Data: A Marginal Modeling Approach","author":"Prentice","year":"2019"},{"issue":"1","key":"2020082405571572300_ref11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0197-2456(97)00078-0","article-title":"Design of the Women\u2019s Health Initiative clinical trial and observational study","volume":"19","author":"The Women\u2019s Health Initiative Study Group","year":"1998","journal-title":"Control Clin Trials"},{"issue":"3","key":"2020082405571572300_ref12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"14","key":"2020082405571572300_ref13","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"2020082405571572300_ref14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/GME.0000000000001067","article-title":"Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women\u2019s Health Initiative hormone therapy trials","volume":"25","author":"Swica","year":"2018","journal-title":"Menopause"},{"issue":"3","key":"2020082405571572300_ref15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1740774507079252","article-title":"Monitoring and reporting of the Women\u2019s Health Initiative randomized hormone therapy trials","volume":"4","author":"Anderson","year":"2007","journal-title":"Clin Trials"},{"issue":"4","key":"2020082405571572300_ref16","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"key":"2020082405571572300_ref17","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2002","edition":"2nd"},{"issue":"20","key":"2020082405571572300_ref18","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/archinte.168.20.2245","article-title":"Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women\u2019s Health Initiative trials of hormone therapy","volume":"168","author":"Rossouw","year":"2008","journal-title":"Arch Intern Med"},{"issue":"6","key":"2020082405571572300_ref19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pctr.0020028","article-title":"Can biomarkers identify women at increased stroke risk? The Women\u2019s Health Initiative hormone trials","volume":"2","author":"Kooperberg","year":"2007","journal-title":"PLoS Clin Trials"},{"issue":"12","key":"2020082405571572300_ref20","doi-asserted-by":"crossref","first-page":"121.1","DOI":"10.1186\/gm121","article-title":"Postmenopausal estrogen and progestin effects on the serum proteome","volume":"1","author":"Pitteri","year":"2009","journal-title":"Genome Med"},{"issue":"7","key":"2020082405571572300_ref21","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00125-004-1448-x","article-title":"Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women\u2019s Health Initiative Hormone Trial","volume":"47","author":"Margolis","year":"2004","journal-title":"Diabetologia"},{"issue":"3","key":"2020082405571572300_ref22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00125-005-0096-0","article-title":"The effect of conjugated equine oestrogen on diabetes incidence: the Women\u2019s Health Initiative randomised trial","volume":"49","author":"Bonds","year":"2006","journal-title":"Diabetologia"},{"issue":"15","key":"2020082405571572300_ref23","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA"},{"issue":"5","key":"2020082405571572300_ref24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women\u2019s Health Initiative randomised placebo-controlled trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020082405571572300_ref25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/aje\/kwp115","article-title":"Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause","volume":"170","author":"Prentice","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2020082405571572300_ref26","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/bcr3632","article-title":"Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects","volume":"16","author":"Zhao","year":"2014","journal-title":"Breast Cancer Res"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwaa033\/33433745\/kwaa033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/189\/9\/972\/33676126\/kwaa033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/189\/9\/972\/33676126\/kwaa033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T09:58:42Z","timestamp":1598263122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/189\/9\/972\/5822983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,4,21]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwaa033","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,4,21]]}}}